Background
Depression
Antidepressants
Duloxetine
Beneficial effects of duloxetine
First author (year of publication) | Title | Design | Published protocol | Sources of information | No of trials | No of participants | Assessment of bias in included trials | Conclusions: remission/response duloxetine versus placebo | Conclusions: adverse effects duloxetine versus placebo |
---|---|---|---|---|---|---|---|---|---|
Krause et al. (2019) [29] | Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis | Systematic review, pairwise and network meta-analysis | Yes | MEDLINE, Embase, PsycINFO, Cochrane Library, ClinicalTrials.gov, WHO registry, reference searches | 4 | 1347 | Yes | Superior: response defined as ≥ 50% reduction on HAM-D, MADRS, BDI or any other validated depression scale, score (1, 2) on CGI-improvement scale. Remission defined as ≤ 7 on HAM-D, ≤ 10 on MADRS, score (1,2) on CGI- severity scale, other criteria as defined in the primary trials. | Inferior: nausea, sedation, dizziness, diarrhea, hyperhidrosis, anticholinergic side effects, higher number of drop-outs due to adverse events. |
Sobieraj et al. (2019) [30] | Adverse effects of pharmacologic treatments of major depression in older adults | Systematic review and meta-analysis | Yes | MEDLINE, Embase, Cochrane Central, PsycINFO, ClinicalTrials.gov, International Controlled Trials Registry | 3 | 977 | Yes | Not assessed | Superior with exception of falls. Higher number of drop-outs due to adverse events. |
Cipriani et al. (2018) [24] | Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis | Systematic review and network meta-analysis | Yes | Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, PsycINFO, AMED, UK National Research Register, ClinicalTrials.gov, websites of regulatory agencies, International Trial Registers | 23 | 6733 | Yes | Superior: response defined as ≥ 50% reduction of the total score on a standardised observer-rating scale for depression. Remission defined as ≤ 7 or 8 on HAM-D, ≤ 10 or 11 on MADRS or remission on any other standardised rating scale for depression. | Inferior: higher number of drop-outs due to adverse events. |
Tham et al. (2016) [31] | Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder—a systematic review and a meta-analysis | Systematic review and meta-analysis | Yes | PubMed, Embase, Cochrane Library, CINAL, PsycINFO, Scopus | 3 | 977 | Yes | Superior: response defined as ≥ 50% post-treatment reduction of scores on HAM-D-17, -21, -24 or MADRS-interview based. Remission was defined depending upon the depression scale used. | Inferior: dry mouth, constipation, diarrhea, dizziness. |
Sharma et al. (2016) [32] | Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports | Systematic review and meta-analysis | No | European and UK drug regulators, Eli Lilly’s website | 12 | Not clear | No (tools not sufficient) | Not assessed | No evidence of increased risk in adults (questionable due to quality of available data). |
Thorlund et al. (2015) [33] | Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis | Network meta-analysis | No | MEDLINE, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, Web of Science, ClinicalTrials.gov, conference proceedings of major psychiatric conferences for the past 2 years | 1 | 311 | No | Superior: partial response defined as 50% reduction on HAM-D or MADRS. | Inferior: dizziness. |
Casale et al. (2012) [34] | Duloxetine in the treatment of elderly people with major depressive disorder | Systematic review | No | MEDLINE, Embase, PsycLIT | 4 | 1132 | No | Superior: reduction in scores on depression scales used in primary trials such as HAM-D-17 and HAM-D-24. | Slightly inferior: dry mouth, diarrhea, nausea, fatigue, insomnia, decreased appetite and libido. |
Schueler et al. (2011) [35] | A systematic review of duloxetine and venlafaxine in major depression, including unpublished data | Meta-analysis | Yes | MEDLINE, Embase, PsycINFO, Psyndex, Cochrane Central Register of Controlled Trials, CDSR, DARE, Cochrane HTA, ClinicalTrials.gov, reference searches, unpublished data (Eli Lilly and Company) | 12 | 3069 | Yes | Superior: response and remission as defined in the primary trials. | Inferior: higher rate of discontinuation due to adverse events. |
Nelson JC. (2010) [36] | Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials | Pooled analysis of individual patient data | No | Eli Lilly and Company sponsored trials | 11 | 2841 | No | Superior: response defined as ≥ 50% improvement on HAM-D. Remission defined as endpoint HAM-D score ≤ 7. | Not assessed |
Mancini et al. (2010) [37] | Use of duloxetine in patients with an anxiety disorder or with comorbid anxiety and major depressive disorder: a review of the literature | Systematic review | No | MEDLINE, Embase | 16 | Not stated | No | Superior: HAM-D-17 total scores at end point, change in HAM-D. | Inferior: nausea, headache, dizziness, fatigue, suicidal thoughts, overdose. |
Gartlehner et al. (2009) [38] | The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis | Systematic review and meta-analysis | No | MEDLINE, Embase, PsychLIT, Cochrane Library, International Pharmaceutical Abstracts | 11 | Not stated | Yes | Superior: remission defined as endpoint score of ≤ 7 on HAMD-17), could not perform meta-analysis due to insufficient data. | Lack of definite evidence but increased risk for adverse effects. |
Mukai et al. (2009) [39] | Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants | Systematic review | No | MEDLINE, PsycINFO, PubMed | 1 | 311 | No | Superior: change in HAM-D scores, GDS scores, cognitive score. | No difference in number of drop- outs. |
Frampton et al. (2007) [40] | Duloxetine: a review of its use in the treatment of major depressive disorder | Systematic review | No | MEDLINE, Embase, AdisBase | 8 | 1881 | No | Superior: response defined as 50% reduction from baseline in HAM-D-17 scores at last observation. Remission defined as endpoint HAM-D score ≤ 7. | Inferior: nausea, dry mouth, constipation, insomnia, dizziness, fatigue, somnolence, decreased appetite, sexual dysfunction. |
Mallinckrodt et al. (2006) [41] | Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range | Pooled analyses | No | Eli Lilly and Company sponsored trials | 4 | 868 | No | Superior: mean change in HAM-D-17 total scores. Response defined as 50% reduction in HAM-D-17 total scores from baseline. Remission defined as HAM-D score ≤ 7. | Inferior: higher rate of discontinuation due to adverse events. |
Acharya et al. (2006) [42] | Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder | Meta-analysis | No | Eli Lilly and Company, Shionogi Company Ltd | 12 | 2996 | No | Not assessed | No evidence of increased risk. |
Vis et al. (2005) [43] | Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials | Meta-analysis | No | Cochrane, Embase, MEDLINE | 6 | 1481 | No | Superior: response defined as improvement of ≥ 50% from baseline on HAM-D or MADRS. Remission defined as HAM-D score ≤ 7 or MADRS ≤ 10. | Inferior: higher number of drop- outs due to adverse effects. |
Harmful effects of duloxetine
Evidence assessments of duloxetine for major depressive disorder
Objectives
Methods
Eligibility criteria
Trials
Participants
Intervention
Control
Co-interventions
Outcomes
Primary outcomes
-
The difference between the mean values from the two intervention groups using the 17-item or the 21-item Hamilton Depression Rating Scale (HDRS) [66]. Where the 21-item scale is used, we will only include the result of the score based on the 17-item version.
-
The proportion of participants with one or more serious adverse events. We will use the International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use—Good Clinical Practice (ICH-GCP) definition of a serious adverse event, which is any untoward medical occurrence that resulted in death, was life-threatening, required hospitalisation or prolonging of existing hospitalisation and resulted in persistent or significant disability or jeopardised the participant [67]. If the trialists do not use the ICH-GCP definition, we will include the data if the trialists use the term ‘serious adverse event’. If the trialists do not use the ICH-GCP definition nor use the term serious adverse event, then we will also include the data if the event clearly fulfils the ICH-GCP definition for a serious adverse event.
Secondary outcomes
-
The proportion of participants with either a suicide or a suicide attempt (as defined by the trialists).
-
Quality of life (assessed with any valid continuous quality of life scale such as quality of life in depression scale, EQ-5D or any other scale used by the trialists).
-
Suicide ideation (assessed using, e.g. Columbia-Suicide Severity Rating Scale).
Exploratory outcomes
-
The SDM [66] between the two intervention groups including trials that use any form of HDRS, Montgomery-Asberg Depression Rating Scale (MADRS) [68] or Beck’s Depression Inventory (BDI) [69]. If the trialists report other scales in addition to HDRS, we will use HDRS-17 in this meta-analysis. If HDRS-17 is not reported, we will use HDRS-21 followed by HDRS-6. Similarly, if the trials report both MADRS and BDI, we will use MADRS in the meta-analysis. We will back-calculate mean difference on HDRS from the SDM.
-
The proportion of participants achieving response. We have defined response as a 50% reduction (from baseline) on either HDRS, MADRS or any other scale as used by trialists, in the stated order of preference.
-
The proportion of participants achieving remission. We have, pragmatically, defined remission as a HDRS less than 8, MADRS less than 10 and BDI less than 10 points, in the stated order of preference.
-
The proportion of participants with one or more adverse events not considered serious.
-
The serious adverse events individually as stated by the trialists.
-
The adverse events not considered serious individually as stated by the trialists.
Assessment time points
Search methods
Screening of trials
Data extraction
Risk of systematic error (bias)
Bias arising from the randomisation process | |
Low risk of bias | (i.) The allocation sequence was adequately concealed |
AND | |
(ii.1) any baseline differences observed between intervention groups appear to be compatible with chance | |
OR | |
(ii.2) there is no information about baseline imbalances | |
AND | |
(iii.1) the allocation sequence was random | |
OR | |
(iii.2) there is no information about whether the allocation sequence was random | |
Some concerns | (i.1) The allocation sequence was adequately concealed |
AND | |
(i.2.1) the allocation sequence was not random | |
OR | |
(i.2.2) baseline differences between intervention groups suggest a problem with the randomisation process | |
OR | |
(ii.1) there is no information about concealment of the allocation | |
AND | |
(ii.2) any baseline differences observed between intervention groups appear to be compatible with chance | |
OR | |
(iii) there is no information to answer any of the signalling questions | |
High risk of bias | (i.) The allocation sequence was not adequately concealed |
OR | |
(ii.1) there is no information about concealment of the allocation sequence | |
AND | |
(ii.2) baseline differences between intervention groups suggest a problem with the randomisation process | |
Bias due to deviation from intended interventions | |
Low risk of bias | (i.1) Participants, carers and people delivering the interventions were unaware of intervention groups during the trial |
OR | |
(i.2.1) participants, carers or people delivering the interventions were aware of intervention groups | |
AND | |
(i.2.2) [if applicable] the important non-protocol interventions were balanced across intervention groups | |
AND (ii) [if applicable] failures in implementing the intervention could not have affected the outcome | |
AND | |
(iii) [if applicable] study participants adhered to the assigned intervention regimen. | |
Some concerns | (i.1.1) Participants, carers and people delivering the interventions were unaware of intervention groups during the trial |
AND | |
(i.1.2.1) [if applicable] failures in implementing the intervention could have affected the outcome | |
OR | |
(i.1.2.2) [if applicable] study participants did not adhere to the assigned intervention regimen | |
OR | |
(i.2.1) participants, carers or people delivering the interventions were aware of intervention groups and (i.2.2) [if applicable] the important non-protocol interventions were balanced across intervention groups | |
AND | |
(i.2.3.1) [if applicable] failures in implementing the intervention could have affected the outcome | |
OR | |
(i.2.3.2) [if applicable] study participants did not adhere to the assigned intervention regimen | |
OR | |
(i.3.1) participants, carers or people delivering the interventions were aware of intervention groups | |
AND | |
(i.3.2) [if applicable] the important non-protocol interventions were not balanced across intervention groups | |
AND | |
(ii) an appropriate analysis was used to estimate the effect of adhering to intervention. | |
High risk of bias | (i.1.1) Participants, carers and people delivering the interventions were unaware of intervention groups during the trial |
AND | |
(i.1.2.1) [if applicable] failures in implementing the intervention could have affected the outcome | |
OR | |
(i.1.2.2) [if applicable] study participants did not adhere to the assigned intervention regimen | |
OR | |
(i.2.1) participants, carers or people delivering the interventions were aware of intervention groups | |
AND | |
(i.2.2) [if applicable] the important non-protocol interventions were balanced across intervention groups | |
AND | |
(i.2.3.1) [if applicable] failures in implementing the intervention could have affected the outcome | |
OR | |
(i.2.3.2) [if applicable] study participants did not adhere to the assigned intervention regimen | |
OR | |
(i.3.1) participants, carers or people delivering the interventions were aware of intervention groups | |
AND | |
(i.3.2) [if applicable] the important non-protocol interventions were not balanced across intervention groups | |
AND | |
(ii) an appropriate analysis was not used to estimate the effect of adhering to intervention | |
Bias due to missing outcome data | |
Low risk of bias | (i.) Outcome data were available for all, or nearly all, randomised participants |
OR | |
(ii.) there is evidence that the result was not biased by missing outcome data | |
OR | |
(iii) missingness in the outcome could not depend on its true value. | |
Some concerns | (i.) Outcome data were not available for all, or nearly all, randomized participants |
AND | |
(ii.) there is not evidence that the result was not biased by missing outcome data | |
AND | |
(iii.) missingness in the outcome could depend on its true value | |
AND | |
(iv) it is not likely that missingness in the outcome depended on its true value. | |
High risk of bias | (i.) Outcome data were not available for all, or nearly all, randomized participants |
AND | |
(ii.) there is not evidence that the result was not biased by missing outcome data | |
AND | |
missingness in the outcome could depend on its true value | |
AND | |
(iv) it is likely that missingness in the outcome depended on its true value | |
Bias in measurement of outcomes | |
Low risk of bias | (i.) The method of measuring the outcome was not inappropriate |
AND | |
(ii.) the measurement or ascertainment of the outcome did not differ between intervention groups | |
AND | |
(iii.1) the outcome assessors were unaware of the intervention received by study participants | |
OR | |
(iii.2) the assessment of the outcome could not have been influenced by knowledge of the intervention received. | |
Some concerns | (i.1) The method of measuring the outcome was not inappropriate |
AND | |
(i.2) the measurement or ascertainment of the outcome did not differ between intervention groups | |
AND | |
(i.3) the assessment of the outcome could have been influenced by knowledge of the intervention received | |
AND | |
(i.4) it is unlikely that assessment of the outcome was influenced by knowledge of intervention received | |
OR | |
(ii.1) the method of measuring the outcome was not inappropriate | |
AND | |
(ii.2) there is no information on whether the measurement or ascertainment of the outcome could have differed between intervention groups | |
AND | |
(ii.3.1) the outcome assessors were unaware of the intervention received by study participants | |
OR | |
(ii.3.2) the assessment of the outcome could not have been influenced by knowledge of the intervention received. | |
High risk of bias | (i.) The method of measuring the outcome was inappropriate |
OR | |
(ii.) the measurement or ascertainment of the outcome could have differed between intervention groups | |
OR | |
(iii) it is likely that assessment of the outcome was influenced by knowledge of the intervention received | |
Bias arising from selective reporting of results | |
Low risk of bias | (i.) The data were analysed in accordance with a pre-specified plan that was finalised before unblinded outcome data were available for analysis |
AND | |
(ii) the result being assessed is unlikely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain | |
AND | |
(iii) reported outcome data are unlikely to have been selected, on the basis of the results, from multiple eligible analyses of the data | |
Some concerns | (i.1) The data were not analysed in accordance with a pre-specified plan that was finalised before unblinded outcome data were available for analysis |
AND | |
(i.2) the result being assessed is unlikely to have been selected, on the basis of t he results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain | |
AND | |
(i.3) the result being assessed is unlikely to have been selected, on the basis of the results, from multiple eligible analyses of the data | |
OR | |
(ii) there is no information on whether the result being assessed is likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain and from multiple eligible analyses of the data. | |
High risk of bias | (i.) The result being assessed is likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain |
OR | |
(ii) the result being assessed is likely to have been selected, on the basis of the results, from multiple eligible analyses of the data |
Overall assessment of risk of bias
Assessment of publication bias and for-profit bias
Differences between the protocol and the review
Statistical methods
Missing outcomes
Sensitivity analyses
-
‘Best-worst-case’ scenario: we will assume that all participants lost to follow-up in the antidepressant group had a beneficial outcome, i.e. survived, had no serious adverse events, had no suicides or suicide attempts and had no non-serious adverse events, and that all those participants lost to follow-up in the control group had a harmful outcome, i.e. did not survive, had a serious adverse event, died by suicide or had a suicide attempt and had a non-serious adverse event.
-
‘Worst-best-case’ scenario: we will assume that all participants lost to follow-up in the antidepressant group had a harmful outcome, i.e. did not survive, had a serious adverse event, died by suicide or had a suicide attempt and had a non-serious adverse event, and that all those participants lost to follow-up in the control group had a beneficial outcome, i.e. survived, had no serious adverse events, had no suicides or suicide attempts and had no non-serious adverse events. When analysing continuous outcomes like depressive symptoms and quality of life, a ‘beneficial outcome’ will be reduction in depression scores and increase in quality of life scale and will be calculated as group (intervention or control) mean plus two SDs (we will secondly use one SD in another sensitivity analysis) of the group mean. Similarly, ‘harmful outcome’ will be increase in depression scores and decrease in quality of life scale and will be calculated as the group mean minus two SDs (we will secondly use one SD in another sensitivity analysis) of the group mean [68]. This data imputation with 2 SDs will provide a possible range of influence that missing data might have on the results [87]. To assess the potential impact of missing data for continuous outcomes, we will perform the following sensitivity analysis:
-
Where SDs are missing and it is not possible to calculate them, we will impute SDs from trials with similar populations and low risk of bias. If we find no such trials, we will impute SDs from trials with a similar population. As the final option, we will impute SDs from all trials.
-
We will perform sensitivity analysis to assess the effect of using ICH-GCP definition of serious adverse events.